全文获取类型
收费全文 | 4371篇 |
免费 | 525篇 |
国内免费 | 114篇 |
出版年
2024年 | 21篇 |
2023年 | 173篇 |
2022年 | 226篇 |
2021年 | 346篇 |
2020年 | 310篇 |
2019年 | 442篇 |
2018年 | 290篇 |
2017年 | 190篇 |
2016年 | 180篇 |
2015年 | 259篇 |
2014年 | 291篇 |
2013年 | 400篇 |
2012年 | 239篇 |
2011年 | 210篇 |
2010年 | 143篇 |
2009年 | 124篇 |
2008年 | 142篇 |
2007年 | 130篇 |
2006年 | 124篇 |
2005年 | 139篇 |
2004年 | 83篇 |
2003年 | 81篇 |
2002年 | 88篇 |
2001年 | 41篇 |
2000年 | 38篇 |
1999年 | 29篇 |
1998年 | 30篇 |
1997年 | 35篇 |
1996年 | 18篇 |
1995年 | 19篇 |
1994年 | 25篇 |
1993年 | 26篇 |
1992年 | 19篇 |
1991年 | 15篇 |
1990年 | 10篇 |
1989年 | 9篇 |
1988年 | 16篇 |
1987年 | 8篇 |
1986年 | 9篇 |
1985年 | 9篇 |
1984年 | 9篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1979年 | 5篇 |
1978年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有5010条查询结果,搜索用时 15 毫秒
1.
Comment on: Rokavec M, et al. Mol Cell 2012; 45:777-89. 相似文献
2.
3.
4.
Interleukin (IL)-6, a cytokine featuring redundancy and pleiotropic activity, contributes to host defense against acute environmental stress, while dysregulated persistent IL-6 production has been demonstrated to play a pathological role in various autoimmune and chronic inflammatory diseases. Targeting IL-6 is thus a rational approach to the treatment of these diseases. Indeed, clinical trials of tocilizumab, a humanized anti-IL-6 receptor antibody have verified its efficacy and tolerable safety for patients with rheumatoid arthritis, Castleman''s disease and systemic juvenile idiopathic arthritis, resulting in approval of this innovative biologic for treatment of these diseases. Moreover, a considerable number of case reports and pilot studies of off-label use of tocilizumab point to the beneficial effects of tocilizumab for a variety of other phenotypically different autoimmune and chronic inflammatory diseases. Elucidation of the source of IL-6 and of mechanisms through which IL-6 production is dysregulated can thus be expected to lead to clarification of the pathogenesis of various diseases. 相似文献
5.
《Developmental cell》2020,52(6):714-730.e5
- Download : Download high-res image (188KB)
- Download : Download full-size image
6.
《Developmental cell》2022,57(18):2221-2236.e5
- Download : Download high-res image (185KB)
- Download : Download full-size image
7.
《European journal of cell biology》2022,101(3):151234
Patients with idiopathic pulmonary fibrosis (IPF) have a high risk of developing lung cancer compared with the general population. The morbidity of lung cancer in IPF patient ranges from 3% to 22%, and in some cases exceeds 50%, and these patients have a reduced survival time. However, the mechanisms through which IPF increases the morbidity and mortality in lung cancer remain unclear.By carefully analyzing the pathological features of these two diseases, we uncovered that, first, similar to IPF, lung carcinomas are more frequently found in the peripheral area of the lungs and, second, lung cancers tend to develop from the honeycomb areas in IPF. In accordance with the above pathological features, due to the spatial location, the peripheral areas of the lung experience a high stretch force because the average distance between adjacent alveolar cells in this area tends to be larger than that at the central lung when inflated; furthermore, the honeycomb areas, comprised of condensed fibrous tissue, are characterized by increased stiffness. Both of these pathological features of lung cancer and IPF are coincidentally related to abnormal mechanical forces (stretch and tissue stiffness). Therefore, we believe that the aberrant mechanical forces that are generated in the lung with IPF may contribute to the onset and progression of lung cancer.In this review, we discuss the possible effects of mechanical forces that are generated in IPF on the initiation and progression of lung cancer from the perspective of the hallmarks of cancer, including proliferation, metastasis, angiogenesis, cancer stem cells, immunology, epigenetics, and metabolism, so as to advance our understanding of the pathogenesis of IPF-related lung cancer and to harness these concepts for lung cancer mechanotherapies. 相似文献
8.
Zhaohua Zhang LiLi Ge Shanshan Zhang Jue Wang Wen Jiang Qian Xin Yun Luan 《Journal of cellular and molecular medicine》2020,24(23):13938
The aim of the study was to explore the mechanism of mesenchymal stem cell‐derived exosomes (MSC‐EXO) to protect against experimentally induced pulmonary hypertension (PH). Monocrotaline (MCT)‐induced rat model of PH was successfully established by a single intraperitoneal injection of 50 mg/kg MCT, 3 weeks later the animals were treated with MSC‐EXO via tail vein injection. Post‐operation, our results showed that MSC‐EXO could significantly reduce right ventricular systolic pressure (RVSP) and the right ventricular hypertrophy index, attenuate pulmonary vascular remodelling and lung fibrosis in vivo. In vitro experiment, the hypoxia models of pulmonary artery endothelial cell (PAEC) and pulmonary vascular smooth muscle cell (PASMC) were used. We found that the expression levels of Wnt5a, Wnt11, BMPR2, BMP4 and BMP9 were increased, but β‐catenin, cyclin D1 and TGF‐β1 were decreased in MSC‐EXO group as compared with MCT or hypoxia group in vivo or vitro. However, these increased could be blocked when cells were transfected with Wnt5a siRNA in vitro. Taken together, these results suggested that the mechanism of MSC‐EXO to prevent PH vascular remodelling may be via regulation of Wnt5a/BMP signalling pathway. 相似文献
9.
10.
J. Sherrod DeVerse Keith A. Bailey Greg A. Foster Vaishali Mittal Stuart M. Altman Scott I. Simon Anthony G. Passerini 《Journal of visualized experiments : JoVE》2012,(65)
Atherogenesis is potentiated by metabolic abnormalities that contribute to a heightened state of systemic inflammation resulting in endothelial dysfunction. However, early functional changes in endothelium that signify an individual''s level of risk are not directly assessed clinically to help guide therapeutic strategy. Moreover, the regulation of inflammation by local hemodynamics contributes to the non-random spatial distribution of atherosclerosis, but the mechanisms are difficult to delineate in vivo. We describe a lab-on-a-chip based approach to quantitatively assay metabolic perturbation of inflammatory events in human endothelial cells (EC) and monocytes under precise flow conditions. Standard methods of soft lithography are used to microfabricate vascular mimetic microfluidic chambers (VMMC), which are bound directly to cultured EC monolayers.1 These devices have the advantage of using small volumes of reagents while providing a platform for directly imaging the inflammatory events at the membrane of EC exposed to a well-defined shear field. We have successfully applied these devices to investigate cytokine-,2 lipid-3, 4 and RAGE-induced5 inflammation in human aortic EC (HAEC). Here we document the use of the VMMC to assay monocytic cell (THP-1) rolling and arrest on HAEC monolayers that are conditioned under differential shear characteristics and activated by the inflammatory cytokine TNF-α. Studies such as these are providing mechanistic insight into atherosusceptibility under metabolic risk factors. 相似文献